South Korea's three leading botulinum toxin manufacturers—Daewoong (Nabota), Medytox, and Hugel—posted combined Q2 revenue of ₩225.9 billion, with Nabota surpassing ₩100 billion in quarterly sales for the first time. The milestone reflects accelerating international demand, particularly in Middle East and Southeast Asian markets where Korean toxins have gained share against incumbent brands.